Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

xtremdelt8 Feb. 4 at 1:59 PM

$ABBV Yikes

0 · Reply

crtlabz Feb. 4 at 1:48 PM

$ABBV

0 · Reply

InsuranceSalesman Feb. 4 at 1:46 PM

$MLTX $LILY.X $MRK and $ABBV all reported and beat estimates this week. Flush with cash and nothing to do with it!

0 · Reply

UgoGreg Feb. 4 at 1:45 PM

$ABBV https://youtu.be/xtKth-XTras

0 · Reply

cmgventure Feb. 4 at 1:45 PM

$ABBV | AbbVie beat earnings and revenue estimates in Q4 and provided strong FY guidance. The stock is -2.9% this morning. 🔹 EPS: $2.71 vs. $2.65 est. ✅ 🔹 Revenue: $16.62B vs. $16.41B est. ✅ Key takeaways: 🔸 Skyrizi revenue: +33% YoY 🔸 Rinvoq revenue: +30% YoY 🔸 Humira revenue: -26% YoY 🔸 IPR&D: $1.27B (-$0.71 EPS impact) 🔸 FY EPS outlook: $14.37-$14.57 ($14.27 est.)

0 · Reply

LinSmi Feb. 4 at 1:44 PM

$ABBV 🚨 $0.90 is a discount price for what this company is about to do. With explosive growth in clean energy and EV infrastructure, this is where the money’s at. 💥

0 · Reply

scottybebs Feb. 4 at 1:41 PM

$ABBV great quarter - stupid reaction

1 · Reply

OpenOutcrier Feb. 4 at 1:36 PM

$ABBV (-1.7% pre) AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results https://ooc.bz/l/91910

0 · Reply

TalkMarkets Feb. 4 at 1:30 PM

Q4 Earnings Summary: Eli Lilly And AbbVie Beat, Uber Mixed $LLY $ABBV $UBER https://talkmarkets.com/content/stocks--equities/q4-earnings-summary-eli-lilly-and-abbvie-beat-uber-mixed?post=554987&userid=166882

0 · Reply

Tokenist Feb. 4 at 1:28 PM

💊🚗 Q4 Earnings Check: Pharma Flexes, Uber Stumbles 🔥 $LLY crushed it. Q4 EPS $7.54 vs $7.20 est, revenue $19.3B vs $17.9B as Mounjaro & Zepbound keep printing money. Lilly guided 2026 revenue to $80–83B with EPS up to $35 . Obesity + pipeline dominance = bulls in control. 💉 $ABBV also delivered. EPS $2.71 vs $2.65, revenue $16.6B vs $16.4B. Skyrizi & Rinvoq carried the load, offsetting oncology softness. 2026 EPS guide $14.37–$14.57 keeps the cash-flow story intact. 🚕 $UBER ? Mixed bag. EPS missed ($0.71 vs $0.80), but revenue beat at $14.4B. Mobility & Delivery grew, but investment revaluations hit profits. Q1 Gross Bookings guide still strong (+17–21% YoY), yet execution risk remains. 📊 Bottom line: Pharma is firing on all cylinders. Uber’s growth engine is running, just not smoothly. Bulls pick their lanes.

1 · Reply

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:18 AM EST - 42 minutes ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 7:51 AM EST - 1 hour ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:48 AM EST - 1 hour ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 3, 2026, 8:50 AM EST - 1 day ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:00 AM EST - 1 day ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Jan 29, 2026, 10:30 PM EST - 5 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

Jan 29, 2026, 10:10 AM EST - 5 days ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

Jan 29, 2026, 8:00 AM EST - 6 days ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 28, 2026, 8:00 AM EST - 7 days ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 27, 2026, 4:52 PM EST - 7 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

Jan 27, 2026, 9:34 AM EST - 7 days ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 25, 2026, 10:11 PM EST - 9 days ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH

$AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jan 16, 2026, 1:43 PM EST - 18 days ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:35 PM EST - 18 days ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Jan 14, 2026, 5:45 PM EST - 20 days ago

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:01 PM EST - 20 days ago

AbbVie plans to build out its presence in obesity market

Jan 13, 2026, 7:22 AM EST - 22 days ago

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 5:24 AM EST - 22 days ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 12, 2026, 7:03 PM EST - 22 days ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 6:57 PM EST - 22 days ago

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:30 PM EST - 22 days ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 23 days ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 23 days ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 23 days ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 23 days ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Jan 12, 2026, 5:12 AM EST - 23 days ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

Jan 10, 2026, 9:30 AM EST - 24 days ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

Jan 8, 2026, 12:07 PM EST - 26 days ago

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 7:38 AM EST - 27 days ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

Jan 7, 2026, 2:58 PM EST - 27 days ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

Jan 7, 2026, 2:48 PM EST - 27 days ago

AbbVie Near Deal for Revolution Medicines

RVMD

Jan 7, 2026, 8:00 AM EST - 4 weeks ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 6, 2026, 11:43 AM EST - 4 weeks ago

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 7:29 AM EST - 4 weeks ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 4, 2026, 9:04 AM EST - 4 weeks ago

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 3, 2026, 7:30 AM EST - 4 weeks ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

Jan 1, 2026, 10:24 PM EST - 4 weeks ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Dec 31, 2025, 8:47 AM EST - 5 weeks ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 5 weeks ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 6 weeks ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

Dec 14, 2025, 11:30 PM EST - 7 weeks ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

Dec 10, 2025, 8:01 PM EST - 7 weeks ago

AbbVie: Unique Mix Of Growth And Value

Dec 8, 2025, 1:30 AM EST - 2 months ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 3, 2025, 4:53 PM EST - 2 months ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:15 AM EST - 2 months ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 1, 2025, 5:55 AM EST - 2 months ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

xtremdelt8 Feb. 4 at 1:59 PM

$ABBV Yikes

0 · Reply

crtlabz Feb. 4 at 1:48 PM

$ABBV

0 · Reply

InsuranceSalesman Feb. 4 at 1:46 PM

$MLTX $LILY.X $MRK and $ABBV all reported and beat estimates this week. Flush with cash and nothing to do with it!

0 · Reply

UgoGreg Feb. 4 at 1:45 PM

$ABBV https://youtu.be/xtKth-XTras

0 · Reply

cmgventure Feb. 4 at 1:45 PM

0 · Reply

LinSmi Feb. 4 at 1:44 PM

$ABBV 🚨 $0.90 is a discount price for what this company is about to do. With explosive growth in clean energy and EV infrastructure, this is where the money’s at. 💥

0 · Reply

scottybebs Feb. 4 at 1:41 PM

$ABBV great quarter - stupid reaction

1 · Reply

OpenOutcrier Feb. 4 at 1:36 PM

$ABBV (-1.7% pre) AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results https://ooc.bz/l/91910

0 · Reply

TalkMarkets Feb. 4 at 1:30 PM

0 · Reply

Tokenist Feb. 4 at 1:28 PM

1 · Reply

mikesterz7 Feb. 4 at 1:21 PM

$ABBV Q4 2025 Earnings Highlights Adjusted EPS: $2.71, exceeding the $2.65 estimated by analysts. Revenue: $16.62 billion, surpassing the $16.36 billion - $16.39 billion consensus estimates. Revenue Growth: Total net revenues increased 10.0% on a reported basis (9.5% operationally). Key Growth Drivers: The immunology portfolio saw strong, with Skyrizi revenue up 32.5% to $5.01 billion and Rinvoq up 29.5% to $2.37 billion. Neuroscience also grew by 17.9%. Headwinds: Humira revenue fell 25.9% to $1.25 billion due to biosimilar competition. Oncology revenue declined 1.5%. 2026 Outlook and Guidance Full-Year 2026 EPS Guidance: AbbVie expects adjusted diluted EPS in the range of $14.37 to $14.57, which is above the analyst consensus of $14.22.

0 · Reply

AStrokeOfLuck Feb. 4 at 1:17 PM

$ABBV

0 · Reply

Gebinator Feb. 4 at 1:17 PM

$ABBV "Global net revenues from the oncology portfolio were $1.664 billion, a decrease of 1.5 percent on a reported basis, or 2.5 percent on an operational basis. Global Imbruvica net revenues were $671 million, a decrease of 20.8 percent. Global Venclexta net revenues were $710 million, an increase of 8.6 percent on a reported basis, or 6.4 percent on an operational basis. Global Elahere net revenues were $182 million, an increase of 22.6 percent on a reported basis, or 21.3 percent on an operational basis." $ABBV needs $SLS for GPS, GPS+, SLS009 - and if an all-inclusive deal is consummated this year - it could also include NPS (NeuVax).

0 · Reply

shoagh12 Feb. 4 at 1:16 PM

$ABBV

0 · Reply

koditrump Feb. 4 at 1:15 PM

$ABBV $NVO

0 · Reply

Nightdawgs21 Feb. 4 at 1:07 PM

$ABBV that’s ok. I’ll buy more. Thank you for the cheap shares

0 · Reply

robby44 Feb. 4 at 1:05 PM

$ABBV always down on earnings - jeez

0 · Reply

grnstock Feb. 4 at 1:04 PM

$ABBV beat and raised. GL

0 · Reply

CapitalInsightHub Feb. 4 at 1:01 PM

$ABBV AbbVie Q4 Sonuçları: Non-GAAP EPS: 10,00 $ → Beklenti 2,65 $’ı aşarak 7,35 $ farkla geçti Gelir: 16,62 Milyar $ → Beklenti 16,42 Milyar $’ı geçti (+10,1% Y/Y) Bölgesel Performans: İmmünoloji: 8,626 Milyar $ (+18,3% raporlanmış / +17,7% operasyonel) Nörobilim: 2,961 Milyar $ (+17,9% / +17,3%) Onkoloji: 1,664 Milyar $ (-1,5% / -2,5%) 💡 2026 Öngörüsü: Ayarlanmış seyreltilmiş EPS 14,37 – 14,57 $ aralığında (piyasa beklentisi 14,22 $) AbbVie, özellikle immünoloji ve nörobilim portföyüyle güçlü büyüme gösteriyor, onkoloji biraz geride kalmış.

0 · Reply

Sareptaking Feb. 4 at 1:01 PM

$IRWD 907M net revenue for the year in linzess sales for $ABBV

1 · Reply

StocktwitsEarnings Feb. 4 at 1:01 PM

$ABBV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.02 up 5200.00% YoY • Reported revenue of $16.62B up 10.04% YoY • AbbVie provides 2026 adjusted diluted EPS guidance of $14.37 to $14.57, excluding any impact from acquired IPR&D and milestones expense, as these cannot be reliably forecasted by AbbVie.

0 · Reply

Czreri1 Feb. 4 at 12:57 PM

$ABBV amazing. Does as good as $LLY which is up 10 percent and we will be red

0 · Reply

Market Cap	394.14B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	23.33
Forward PE	15.39
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	8,158,500
Avg Vol	6,197,886
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	73%
Beta	0.36
Analysts	Strong Sell
Price Target	$245.80